GALDERMA GROUP AG (NYSE:GALDY) — Market Cap & Net Worth
Market Cap & Net Worth: GALDERMA GROUP AG (GALDY)
GALDERMA GROUP AG (NYSE:GALDY) has a market capitalization of $48.78 Billion ($48.78 Billion) as of June 17, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #561 globally and #280 in its home market, demonstrating a 3.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GALDERMA GROUP AG's stock price $43.22 by its total outstanding shares 1172843625 (1.17 Billion). Review how much debt does GALDERMA GROUP AG carry to assess the company's total debt and financial obligations.
GALDERMA GROUP AG Market Cap History: 2025 to 2026
GALDERMA GROUP AG's market capitalization history from 2025 to 2026. Data shows growth from $48.61 Billion to $50.69 Billion (0.00% CAGR).
GALDERMA GROUP AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GALDERMA GROUP AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.28x
GALDERMA GROUP AG's market cap is 9.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
79.31x
GALDERMA GROUP AG's market cap is 79.31 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $48.61 Billion | $5.24 Billion | $613.00 Million | 9.28x | 79.31x |
Competitor Companies of GALDY by Market Capitalization
Companies near GALDERMA GROUP AG in the global market cap rankings as of June 17, 2026.
Key companies related to GALDERMA GROUP AG by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #680 globally with a market cap of $40.20 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
| #680 | Haleon plc | NYSE:HLN | $40.20 Billion | $9.09 |
GALDERMA GROUP AG Historical Marketcap From 2025 to 2026
Between 2025 and today, GALDERMA GROUP AG's market cap moved from $48.61 Billion to $ 50.69 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $50.69 Billion | +4.27% |
| 2025 | $48.61 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of GALDERMA GROUP AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.78 Billion USD |
| MoneyControl | $48.78 Billion USD |
| MarketWatch | $48.78 Billion USD |
| marketcap.company | $48.78 Billion USD |
| Reuters | $48.78 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GALDERMA GROUP AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more